SCHEMBL240730

SCHEMBL240730

O=C(CBr)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.70
MEN1 O00255 5/20 0.70
KMT2A Q03164 5/20 0.70
GAA P10253 1/20 0.70
XBP1 P17861 1/20 0.70
NPSR1 Q6W5P4 1/20 0.70
ALDH1A1 P00352 5/20 0.69
SMN1; SMN2 Q16637 1/20 0.67
HDAC3 O15379 1/20 0.63
HDAC1 Q13547 1/20 0.63
HDAC2 Q92769 1/20 0.63
HDAC10 Q969S8 1/20 0.63
HDAC11 Q96DB2 1/20 0.63
HDAC8 Q9BY41 1/20 0.63
HDAC6 Q9UBN7 1/20 0.63
NCOR2 Q9Y618 1/20 0.63
HTT P42858 2/20 0.62
RAB9A P51151 1/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
RECQL P46063 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29485038 1.00 MAPT (0.70) MAPTMEN1KMT2AGAAXBP1
SCHEMBL3045461 0.95 MAPT (0.65) MAPTMEN1KMT2AGAAXBP1
SCHEMBL6410568 0.89 MAPT (0.65) MAPTMEN1KMT2AGAAXBP1
SCHEMBL433736 0.89 MEN1 (0.71) MAPTMEN1KMT2AGAAXBP1
SCHEMBL31236338 0.88 MAPT (0.77) MAPTMEN1KMT2AGAAXBP1
SCHEMBL5142590 0.88 MAPT (0.77) MAPTMEN1KMT2AGAAXBP1
SCHEMBL693942 0.85 MAPT (0.72) MAPTMEN1KMT2AGAAXBP1
SCHEMBL693941 0.85 MAPT (0.72) MAPTMEN1KMT2AGAAXBP1
SCHEMBL26627751 0.85 MAPT (0.72) MAPTMEN1KMT2AGAAXBP1
SCHEMBL2184782 0.84 SMN1; SMN2 (0.71) MAPTMEN1KMT2AGAAXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12623942-B2 Method for extracting salts and temperature- regenerated extracting composition ADIONICS (FR) 2026-05-12 US disclosed
EP-4061961-B1 METHOD FOR DOUBLE STRAND SEQUENCING OXFORD NANOPORE TECH PLC (GB) 2026-04-08 EP disclosed
US-20260072009-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-12 US disclosed
US-20260063618-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE Oxford Nanopore Technolgies PLC (GB) 2026-03-05 US disclosed
EP-4270008-B1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE OXFORD NANOPORE TECH PLC (GB) 2026-02-04 EP disclosed
EP-4127711-B1 METHOD OF DETECTING AN ANALYTE IN A MEDIUM COMPRISING A LIGHT SCATTERING CONSTITUENT KING S COLLEGE LONDON (GB) 2025-12-24 EP disclosed
EP-4662489-A1 METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE Oxford University Innovation Limited (GB) 2025-12-17 EP disclosed
US-20250361552-A1 METHOD AND ADAPTORS OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-11-27 US disclosed
EP-4168582-B1 A METHOD OF SELECTIVELY CHARACTERISING A POLYNUCLEOTIDE USING A DETECTOR OXFORD NANOPORE TECH PLC (GB) 2025-11-19 EP disclosed
US-20250164497-A1 METHOD OF CHARACTERISING POLYPEPTIDES USING A NANOPORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-05-22 US disclosed
US-20060287377-A1 New benzimidazole derivatives ASTRAZENECA AB (SE) 2006-12-21 US disclosed
CN-1784387-A Novel benzimidazole derivatives ASTRAZENECA AB (SE) 2006-06-07 CN disclosed
EP-1660467-A2 AMINOFURAZAN COMPOUNDS AS PROTEIN KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2006-05-31 EP disclosed
EP-1626964-A2 NEW BENZIMIDAZOLE DERIVATIVES AstraZeneca AB (SE) 2006-02-22 EP disclosed
US-20050148640-A1 Aminofurazan compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2005-07-07 US disclosed
WO-2005019190-A2 (4 -AMINO -1,2, 5-OXADIAZOL-4-YL) -HETΞROAROMATIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-03 WO disclosed
WO-2004100865-A2 NEW BENZIMIDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2004-11-25 WO disclosed
US-4944796-A Certain 2-(disubstituted amino) acetanilide herbicides ICI AMERICAS INC. (US) 1990-07-31 US disclosed
US-4891058-A HERBICIDALLY ACTIVE INTERMEDIATES ICI AMERICAS INC. (US) 1990-01-02 US disclosed
US-4102924-A REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS BAYER AKTIENGESELLSCHAFT (DE) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287377-A1 New benzimidazole derivatives CYP2C9, CDK9, CCNI MAPT 2393/4885MEN1 1947/4885KMT2A 2653/4885
US-20050148640-A1 Aminofurazan compounds useful as protein kinase inhibitors PHKG1, MAP3K20, MAP3K5 MAPT 1028/4885MEN1 2135/4885KMT2A 1498/4885
US-20260063618-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE NUP210, NPPA, NUP160 MAPT 2543/4885MEN1 1352/4885KMT2A 4744/4885
US-12623942-B2 Method for extracting salts and temperature- regenerated extracting composition POLQ, NONO, AQP3 MAPT 3057/4885MEN1 4052/4885KMT2A 2402/4885
US-20260072009-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE NUP210, SLC9A2, SLC9A3 MAPT 2784/4885MEN1 446/4885KMT2A 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.